X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-05 | PRGO | Ives Alison | EVP, Chief Scientific Officer | P - Purchase | $27.26 | +2,490 | 15,372 | +19% | +$67,877 | |||||
2024-02-29 | PRGO | Ives Alison | EVP, Chief Scientific Officer | P - Purchase | $26.44 | +1,545 | 12,446 | +14% | +$40,850 | ||||||
| A | 2023-11-16 | PRGO | Ives Alison | EVP, Chief Scientific Officer | P - Purchase | $29.34 | +2,040 | 10,901 | +23% | +$59,854 | |||||
| M | 2024-02-29 | PRGO | Willis Robert | EVP, CHRO | P - Purchase | $25.90 | +6,371 | 25,476 | +33% | +$164,977 | |||||
2024-02-29 | PRGO | Lockwood-Taylor Patrick | CEO | P - Purchase | $26.54 | +9,500 | 20,500 | +86% | +$252,168 | ||||||
2023-11-24 | PRGO | Willis Robert | EVP, CHRO | P - Purchase | $31.01 | +5,550 | 19,105 | +41% | +$172,106 | ||||||
2023-11-16 | PRGO | Ives Alison | EVP, Chief Scientific Officer | P - Purchase | $29.34 | +2,040 | 10,380 | +24% | +$59,854 | ||||||
2023-11-14 | PRGO | Bezerra Eduardo Guarita | EVP, CFO | P - Purchase | $29.18 | +5,000 | 8,428 | +146% | +$145,882 | ||||||
2023-11-14 | PRGO | Lockwood-Taylor Patrick | CEO | P - Purchase | $28.99 | +11,000 | 11,000 | New | +$318,868 | ||||||
2023-06-13 | PRGO | Parker Geoffrey M. | Dir | P - Purchase | $33.06 | +10,000 | 47,084 | +27% | +$330,637 | ||||||
2023-05-23 | PRGO | Andersen Svend | EVP, Pres CHCI | P - Purchase | $33.41 | +2,900 | 82,424 | +4% | +$96,902 | ||||||
2023-05-11 | PRGO | Kessler Murray S | CEO | S - Sale | $35.75 | -197,646 | 2,668 | -99% | -$7,066,358 | ||||||
2023-03-10 | PRGO | Dillard James E III | EVP, Pres CSCA | S - Sale | $35.70 | -9,000 | 25,130 | -26% | -$321,309 | ||||||
2023-03-13 | PRGO | Farrington Thomas | EVP, CIO | S - Sale | $35.57 | -3,723 | 2,823 | -57% | -$132,435 | ||||||
2023-03-08 | PRGO | Janish Ronald Craig | EVP, Gbl Ops, SC, CTO | S - Sale | $36.92 | -4,500 | 25,002 | -15% | -$166,133 | ||||||
2023-03-06 | PRGO | Parker Geoffrey M. | Dir | P - Purchase | $38.05 | +5,000 | 33,040 | +18% | +$190,270 | ||||||
2022-12-16 | PRGO | Quinn Grainne | EVP, Chief Medical Officer | S - Sale | $31.65 | -2,368 | 9,118 | -21% | -$74,947 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |